Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — ESG Presentation (October 2022)
42 slides from Kyowa Kirin's sustainability presentation, Oct 12, 2022
Slide 1: Kyowa Kirin ESG Meeting
Kyowa Kirin ESG Meeting October 12, 2022 Kyowa Kirin’s initiatives for realizing a sustainable society and its business
Slide 2: Forward-looking statements disclaimer
This document contains certain forward‐looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward‐looking statements are based upon information available to the company at the present time and upon reasona
Slide 3: Agenda
Agenda Representative Director of the Board, President Kyowa Kirin’s value creation story and Chief Executive Officer Masashi Miyamoto, Ph.D. Managing Executive Officer, Vice President, Materiality, Improving access to medicines for rare diseases Head of Strategy Division Takeyoshi Yamashita, Ph.D.
Slide 4: Kyowa Kirin's Value Creation Story
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Kyowa Kirin’s Value Creation Story 4 © Kyowa Kirin Co., Ltd.
Slide 5: Our Philosophy and Core Values
Our Philosophy and Core Values OUR PHILOSOPHY Transform lives with passion and excitement. The Kyowa Kirin Group companies Challenge the status quo in all of our work. strive to contribute to the health and wellbeing of people around the world by creating new value through the pursuit of advances in
Slide 6: Our Vision toward 2030
Our Vision toward 2030 Provide pharmaceuticals for unmet medical needs We are focused on developing Our Vision toward 2030 medicines for diseases where there is a clear patient need for new options. We make full use of multiple therapeutic modalities, including biotechnology Kyowa Kirin will realize
Slide 7: Value Creation Story
Local Communities/ Future Generations Value Creation Story Government /Local government Regulators/ Payers Industry Associations Sales, R&D Partners Value creation process Stakeholders (business process) Shareholders/ Investors Suppliers/ Wholesalers etc. Input Strategies for achieving the Output Me
Slide 8: Strategy to Realize our Vision
Strategy to Realize our Vision Maximize the value of global products Launch services that go beyond pharmaceuticals Establish framework to ensure stable global supplies Foster a corporate culture suited to global business Build a drug pipeline to drive growth beyond 2025 development Provid
Slide 9: Materiality
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Materiality 9 © Kyowa Kirin Co., Ltd.
Slide 10: Materiality (January 2021-) Materiality Matrix
Materiality (January 2021-) Materiality Matrix Impact on social sustainability Kyowa Kirin — Make as many people as — Foster even greater trust in Group possible smile — Kyowa Kirin — Growth Growth materiality opportunities Continuous innovation foundations Corporate governance Transparency an
Slide 11: Materiality (October 2022-)
Materiality (October 2022-) Topics for value creation Topics for social value improvement Provide pharmaceutical Creation of innovative drugs Quality assurance and a stable supply products for Maximize product value Retain the trust of society of products unmet medical needs Pipeline expansion
Slide 12: Materiality (October 2022-)
Materiality (October 2022-) Topics for value creation Topics for social value improvement Provide pharmaceutical Creation of innovative drugs Quality assurance and a stable supply products for Maximize product value Retain the trust of society of products unmet medical needs Pipeline expansion
Slide 13: Improving Access to Medicines for Rare Diseases
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Improving Access to Medicines for Rare Diseases 13 © Kyowa Kirin Co., Ltd.
Slide 14: Policy for Access to Medicines
Policy for Access to Medicines Providing medicine Raise awareness for rare diseases of rare diseases Quality Assurance Provide and Stable Supply and Improving pharmaceuticals for Ensuring Patient access to Unmet Medical Needs Safety and medicines Appropriate Use of Medicines The Kyowa Kirin Group be
Slide 15: Providing Medicines for Rare Diseases
Providing medicine for rare diseases Providing Medicines for Rare Diseases Kyowa Kirin has been working to create new drugs for diseases for which there are no effective treatments, including rare diseases, by focusing on their pathological mechanisms. Rare Diseases (designated indications or effect
Slide 16: Raise awareness of rare diseases
Raise awareness of rare diseases Raise awareness of rare diseases 16 © Kyowa Kirin Co., Ltd.
Slide 17: Raise awareness of rare diseases
Raise awareness of rare diseases Raise awareness of rare diseases 17 © Kyowa Kirin Co., Ltd.
Slide 18: Unified team brimming with diversity
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Unified team brimming with diversity 18 © Kyowa Kirin Co., Ltd.
Slide 19: "Talents" = "Source of Innovation"
“Talents” = “Source of Innovation” Considering talents to be the source of innovation, we bring out the best in each member’s ability and develop person and organization that challenge to innovate and continuously create new value. We globally work on ”Diversity, Equity, & Inclusion,” “Employee He
Slide 20: Human Resources Strategy Foundation
Development of talents to contribute to value creation and HR strategy to promote business strategy Cores of Human Resources Strategy 1. Deliver health and well-being Business 2030 Business 2. Talent management Philosophy Vision Strategy 3. Develop environment for diverse talents 4. Reinforce organi
Slide 21: Our DE&I Statement
Our DE&I Statement At Kyowa Kirin, we embrace and proactively promote Diversity, Equity and Inclusion in the workplace as an embodiment of our Core Values. Commitment to Life Diversity, equity and inclusion in our teams enables us to reflect the people and communities we serve and be sensitive to th
Slide 22: DE&I efforts
DE&I efforts Aiming to ensure female leaders in One Kyowa Kirin structure, we set a target of increasing the percentage of global female leaders from 29% in the end of FY2021 to 40% by 2030. Target in Japan: percentage of female managers to be 18% or higher in the end of 2025. To realize Equity,
Slide 23: Global expansion of corporate culture reform
Global expansion of corporate culture reform Expanding corporate culture reform “To go over a wall” activity started in Japan to Regions as ”KABEGOE.” Organizing “One Kyowa Kirin Culture Workshop” in Regions in sequence. In Japan, organizing training targeted at middle management, the key for cor
Slide 24: Kyowa Kirin's Hybrid-Working Model
To bring more smiles to patients around the world Kyowa Kirin’s Hybrid-Working Model Key Principles Kyowa Kirin Group advocates integrating the “Hybrid-Working Model” as our new way of working: To the extent that the selected work arrangements are fully compatible with the nature of Flexibility with
Slide 25: Talent management to assign right person to right place globally
Talent management to assign right person to right place globally Cores of HR Strategy Develop and use talents who can contribute to growth Issue of the business 1. Deliver health and well-being Establish HR foundation with global competitiveness 2. Talent management 3. Develop environment for divers
Slide 26: Global Engagement and Motivation Survey (GEMS)
Global Engagement and Motivation Survey (GEMS) We use the employees’ attitude survey “Global Engagement and Motivation Survey (GEMS)” as an important indicator to make the most of ability of each employee, monitoring “Employee Engagement” and “Employee Enablement” over time. We added “Diversity
Slide 27: Thriving global environment for future generations
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Thriving global environment for future generations 27 © Kyowa Kirin Co., Ltd.
Slide 28: Environmental Management Policy and Issues
Environmental Management Policy and Issues – Reducing Impact on the Global Environment – Business activities are conducted in accordance with the Kyowa Kirin Group Basic Environmental Policy. Aiming to realize a decarbonized society and promote the protection of the global environment for future g
Slide 29: Initiatives Policy and Performance of Climate Change
Initiatives Policy and Performance of Climate Change Contribute to reductions in CO2 emissions as a global issue and disclose information in line with TCFD Recommendations CO2 emissions (Scope 1,2) reduction : Save Energy x Expand Renewable Energy x Convert Energy Sources 2030 Target Transition
Slide 30: Climate Change Disclosure and Risks
Climate Change Disclosure Statement of support for TCFD recommendations (November 2021) Information disclosure (Website, Annual securities reports, Integrated reports) Risks and Opportunities Related to Climate Change Pink: Risk Blue: Opportunity Scenario classification Climate change-related driv
Slide 31: Early Achievement of 2030 CO2 Emission Reduction Targets
Early Achievement of 2030 CO2 Emission Reduction Targets Implement various reduction measures in accordance with the roadmap to achieve the annual target and build a solid track record toward achieving the 2030 target. CO2 Emission Reduction Results and Forecasts < 2020~2030 > Roadmap as of 2022 It
Slide 32: Review of BCP for Large-Scale Natural Disasters
Review of BCP for Large-Scale Natural Disasters, and Disaster Countermeasures for the Facilities Review of BCPs for large-scale natural disasters for each plant to prevent the impact on production activities due to flooding on the plant premises, etc. Implement flood prevention measures against fl
Slide 33: Sound governance system to support value creation
Kyowa Kirin’s initiatives for realizing a sustainable society and its business Sound governance system to support value creation 33 © Kyowa Kirin Co., Ltd.
Slide 34: Response to revised CG code – Ensure further transparency
Response to revised CG code – Ensure further transparency – Independent director ratio of the Board: 56% (5/9 persons) Independent officer ratio of Nomination and Remuneration Consultative Committee: 70% (7/10 persons) Corporate Governance Structure (As of March 25, 2022) Internal Officers Outside
Slide 35: Response to revised CG code – Diverse Board members
Response to revised CG code – Diverse Board members – “Skill Matrix” of Directors and Auditors publicly available Diverse skills including global business management experience Nomination & Professional skills Name Outside Remuneration Corporate Independent Consultative management/ Finance, accoun
Slide 36: Response to revised CG code – Others
Response to revised CG code – Others – Endorsement for TCFD Recommendations (November 2022) Initiated disclosure based on TCFD recommendations on our website Global DE&I Statement (December 2022) Aiming for female ratio of 40% in global leader positions 36 © Kyowa Kirin Co., Ltd.
Slide 37: Decent governance system as a listed subsidiary
Decent governance system as a listed subsidiary “Securing management independence” and “Reasonable cooperation to maintain listing” -> Clearly stated in the Strategic Alliance Agreement Ensuring Important dicision-making such as M&A independence -> To be made on our own (No need for prior endorsem
Slide 38: Enhanced global business operation
Enhanced global business operation Launched “One Kyowa Kirin,” a Region-Function matrix management system, in April 2019 Accurately and rapidly respond to region-specific and global issues Streamline and speed up functions’ operation Added Franchise (product) axis to further Functional dimension
Slide 39: One Kyowa Kirin Leadership
One Kyowa Kirin Leadership Masashi Miyamoto, PhD Yutaka Osawa, MBA Toshifumi Mikayama, PhD Takeyoshi Yamashita, PhD Motohiko Kawaguchi Abdul Mullick, PhD Tan Boon Heon, PhD Chief Executive Officer (CEO) Chief Compliance Officer Chief International Chief Strategy Officer Chief Financial Officer (CFO)
Slide 40: One Kyowa Kirin Leadership
One Kyowa Kirin Leadership Yoshifumi Torii, PhD Ernesto Aycardi Takefumi Matsushita, PhD, MBA Jonathan Patroni, MBA JD Rafizadeh-Kabe, MD, JD Toshiyuki Kurata, MBA Masao Hirokawa Global Research Head Global Development Head Global Medical Global Quality Global Pharmaco- Global Manufacturing Head Glo
Slide 41: Regional supervisory structure
Regional supervisory structure Board organized at each regional headquarters 2 outside directors with rich global pharma experiences appointed, respectively Direct communication with HQs’ independent outside directors started in 2022 Francesco Granata David Ebsworth Olivier Daubry Iris Kang James
Slide 42: Kyowa Kirin
@yOWa KIRIN